LV12291B - COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES - Google Patents
COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES Download PDFInfo
- Publication number
- LV12291B LV12291B LVP-99-27A LV990027A LV12291B LV 12291 B LV12291 B LV 12291B LV 990027 A LV990027 A LV 990027A LV 12291 B LV12291 B LV 12291B
- Authority
- LV
- Latvia
- Prior art keywords
- compound
- alkylene
- hetero
- formula
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LVP-00-31A LV12459B (en) | 1996-07-30 | 2000-02-25 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES |
| LVP-00-30A LV12458B (en) | 1996-07-30 | 2000-02-25 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2313996P | 1996-07-30 | 1996-07-30 | |
| US89577297A | 1997-07-17 | 1997-07-17 | |
| PCT/US1997/013422 WO1998004537A1 (fr) | 1996-07-30 | 1997-07-30 | Nouveaux composes et compositions servant a traiter des maladies associees a l'activite de tryptase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV12291A LV12291A (lv) | 1999-06-20 |
| LV12291B true LV12291B (en) | 2000-04-20 |
Family
ID=26696778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-99-27A LV12291B (en) | 1996-07-30 | 1999-02-18 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0934293A1 (fr) |
| JP (1) | JP2001509787A (fr) |
| KR (1) | KR20000029679A (fr) |
| CN (1) | CN1073103C (fr) |
| AU (1) | AU733621B2 (fr) |
| CA (1) | CA2262542A1 (fr) |
| CZ (1) | CZ29799A3 (fr) |
| EE (1) | EE9900036A (fr) |
| FI (1) | FI990171A (fr) |
| HU (1) | HUP0003267A3 (fr) |
| LV (1) | LV12291B (fr) |
| NO (1) | NO990433L (fr) |
| NZ (1) | NZ333713A (fr) |
| PL (1) | PL331465A1 (fr) |
| SI (1) | SI9720047A (fr) |
| SK (1) | SK8599A3 (fr) |
| WO (1) | WO1998004537A1 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| ES2233025T3 (es) * | 1998-02-06 | 2005-06-01 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Agente inhibidores de la triptasa. |
| US6613769B1 (en) * | 1998-02-06 | 2003-09-02 | Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. | Tryptase inhibitors |
| IL141654A0 (en) * | 1998-09-04 | 2002-03-10 | Byk Gulden Lomberg Chem Fab | Pyranose derivatives and pharmaceutical compositions containing the same |
| ATE279398T1 (de) | 1999-08-10 | 2004-10-15 | Altana Pharma Ag | Diazocindionderivate und ihre verwendung als tryptase inhibitoren |
| EP1216236A1 (fr) * | 1999-09-14 | 2002-06-26 | Byk Gulden Lomberg Chemische Fabrik GmbH | Inhibiteurs de la tryptase |
| WO2001036386A1 (fr) * | 1999-11-17 | 2001-05-25 | Sumitomo Pharmaceuticals Co., Ltd. | Traitement du diabete contenant un derive de dipiperazine |
| DE19955476A1 (de) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| WO2001046128A2 (fr) | 1999-12-20 | 2001-06-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Inhibiteurs de tryptase |
| SI1244643T1 (en) * | 1999-12-20 | 2004-12-31 | Altana Pharma Ag | Tryptase inhibitors |
| US6924305B2 (en) | 2001-01-31 | 2005-08-02 | Altana Pharma Ag | Diazocine derivatives and their use as tryptase inhibitors |
| WO2002066420A2 (fr) * | 2001-02-21 | 2002-08-29 | Altana Pharma Ag | Inhibiteurs de la tryptase |
| DE60217076T2 (de) | 2001-02-21 | 2007-06-21 | Altana Pharma Ag | Tryptaseinhibitoren |
| WO2002074732A2 (fr) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Inhibiteurs de la tryptase |
| JP2004525926A (ja) * | 2001-03-15 | 2004-08-26 | アルタナ ファルマ アクチエンゲゼルシャフト | トリプターゼ阻害剤 |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| IL159299A0 (en) | 2001-06-11 | 2004-06-01 | Xenoport Inc | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| CA2450659A1 (fr) | 2001-06-19 | 2002-12-27 | Altana Pharma Ag | Inhibiteurs de tryptase |
| AU2005301970B2 (en) | 2004-11-04 | 2011-06-02 | Arbor Pharmaceuticals, Llc | Gabapentin prodrug sustained release oral dosage forms |
| US8399519B2 (en) * | 2008-12-19 | 2013-03-19 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
| TWI432188B (zh) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類 |
| FR3038605B1 (fr) | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation |
| CN110869362A (zh) * | 2017-05-12 | 2020-03-06 | 国立研究开发法人理化学研究所 | A类gpcr结合性化合物改性体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845242A (en) * | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
| EP0688337A1 (fr) * | 1993-03-12 | 1995-12-27 | Arris Pharmaceutical Corporation | Compositions et procedes pour le traitement d'affections inflammatoires immunoresultantes |
| US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| WO1995032945A1 (fr) * | 1994-06-01 | 1995-12-07 | Arris Pharmaceutical Corporation | Compositions et procedes de traitement d'etats induits par des mastocytes |
| WO1996009297A1 (fr) * | 1994-09-23 | 1996-03-28 | Arris Pharmaceutical Corporation | Compositions et procedes de traitement de maladies inflammatoires provoquees par les mastocytes |
| CZ298197A3 (cs) * | 1995-03-24 | 1998-03-18 | Arris Pharmaceutical Corporation | Reverzibilní inhibitory proteas |
| TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-07-30 KR KR1019997000757A patent/KR20000029679A/ko not_active Application Discontinuation
- 1997-07-30 SI SI9720047A patent/SI9720047A/sl unknown
- 1997-07-30 CN CN97196877A patent/CN1073103C/zh not_active Expired - Fee Related
- 1997-07-30 JP JP50913698A patent/JP2001509787A/ja active Pending
- 1997-07-30 WO PCT/US1997/013422 patent/WO1998004537A1/fr not_active Application Discontinuation
- 1997-07-30 CA CA002262542A patent/CA2262542A1/fr not_active Abandoned
- 1997-07-30 SK SK85-99A patent/SK8599A3/sk unknown
- 1997-07-30 AU AU39670/97A patent/AU733621B2/en not_active Ceased
- 1997-07-30 PL PL97331465A patent/PL331465A1/xx unknown
- 1997-07-30 EP EP97937066A patent/EP0934293A1/fr not_active Withdrawn
- 1997-07-30 EE EEP199900036A patent/EE9900036A/xx unknown
- 1997-07-30 NZ NZ333713A patent/NZ333713A/xx unknown
- 1997-07-30 CZ CZ99297A patent/CZ29799A3/cs unknown
- 1997-07-30 HU HU0003267A patent/HUP0003267A3/hu unknown
-
1999
- 1999-01-29 NO NO990433A patent/NO990433L/no not_active Application Discontinuation
- 1999-01-29 FI FI990171A patent/FI990171A/fi unknown
- 1999-02-18 LV LVP-99-27A patent/LV12291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ333713A (en) | 2000-12-22 |
| EE9900036A (et) | 1999-08-16 |
| SI9720047A (sl) | 1999-08-31 |
| CA2262542A1 (fr) | 1998-02-05 |
| AU733621B2 (en) | 2001-05-17 |
| PL331465A1 (en) | 1999-07-19 |
| CN1226892A (zh) | 1999-08-25 |
| JP2001509787A (ja) | 2001-07-24 |
| FI990171A0 (fi) | 1999-01-29 |
| WO1998004537A1 (fr) | 1998-02-05 |
| CZ29799A3 (cs) | 1999-06-16 |
| CN1073103C (zh) | 2001-10-17 |
| FI990171A (fi) | 1999-03-23 |
| AU3967097A (en) | 1998-02-20 |
| HUP0003267A2 (hu) | 2001-06-28 |
| KR20000029679A (ko) | 2000-05-25 |
| NO990433L (no) | 1999-03-25 |
| LV12291A (lv) | 1999-06-20 |
| SK8599A3 (en) | 2000-03-13 |
| HUP0003267A3 (en) | 2002-02-28 |
| NO990433D0 (no) | 1999-01-29 |
| EP0934293A1 (fr) | 1999-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV12291B (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES | |
| AU686115B2 (en) | Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation | |
| SU1581221A3 (ru) | Способ получени (4-пиперидинилметил- или гетеро)-пуринов или их фармацевтически приемлемых солей с кислотами, или стереоизомеров | |
| US5607936A (en) | Substituted aryl piperazines as neurokinin antagonists | |
| US7932247B2 (en) | M3 muscarinic acetylcholine receptor antagonists | |
| US20090142279A1 (en) | Novel m3 muscarinic acetylcholine receptor antagonists | |
| CZ87097A3 (en) | Preparation for therapy and therapeutical methods for treating inflammations mediated by mast cells | |
| WO2000027826A1 (fr) | Nouvelles pyrimidines, leur production et leur utilisation | |
| US5574042A (en) | Imidazo [1,2-a] pyridines and their pharmaceutical use | |
| CZ20012562A3 (cs) | Amidové sloučeniny | |
| US6489327B1 (en) | Tryptase inhibitors | |
| EP0224919A2 (fr) | Composés de thiazol, leur procédé de préparation et composition pharmaceutique les contenant | |
| DE4243858A1 (de) | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung | |
| EP1057815B1 (fr) | Composes cycliques d'amide | |
| AU5625499A (en) | Novel pyranoses | |
| CA1305482C (fr) | Derives de la piperidine, leur preparation et leur application en therapie | |
| ES2222259T3 (es) | Inhibidores de triptasa. | |
| US4792554A (en) | Pyridine compounds, pharaceutical compositions, their use in allergy therapy | |
| NZ506614A (en) | Compounds for treating diseases associated with tryptase activity | |
| JPH07330777A (ja) | チエノ［３，２−ｄ］ピリミジン−４−オン誘導体 | |
| MXPA99001105A (en) | Novel compounds and compositions for treating diseases associated with tryptase activity | |
| Kaur et al. | Synthesis and antispasmodic activity evaluation of bis-(papaverine) analogues | |
| LT4587B (lt) | Nauji junginiai ir kompozicijos, skirti gydyti ligas, susijusias su triptazės aktyvumu | |
| AU2002253035B2 (en) | Tryptase inhibitors | |
| LV12459B (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES |